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Background: Basal insulin is a common therapy for insulin initiation in patients with type 2 diabetes
mellitus (T2DM) uncontrolled with oral antidiabetic drugs (OAD). There is limited data for initiating basal
insulin therapy in the elderly population in clinical practice.
Methods: The aim of this study was to analyze 72 Taiwanese patients with T2DM on OAD with glycated
hemoglobin (HbA1c) > 7% who received basal insulin therapy with insulin glargine for 24 weeks in
clinical practice. The patients were divided into an older group ( 65 years, n ¼ 32) and younger group (<
65 years, n ¼ 40) for comparison purposes.
Results: At baseline, the duration of diabetes was longer and the fasting plasma glucose (FPG) level was
slightly lower in the older group versus the younger group. The number of OAD types was signiﬁcantly
reduced after initiation of basal insulin in both groups. After the 24-week treatment of insulin glargine,
the HbA1c and the FPG were signiﬁcantly reduced by 1.18% and 81.3 mg/dL, respectively, in the older
group, and by 1.49% and 93.0 mg/dL, respectively, in the younger group, but did not differ statistically
between the two groups. The mean daily insulin doses in both groups were similar. Body weight
increased signiﬁcantly but it was comparable in older and younger patients. The rate of hypoglycemic
events was low and no difference was found between the two groups.
Conclusion: In elderly people with T2DM in Taiwan who had inadequate glycemic control by OAD,
initiation of basal insulin therapy with insulin glargine over 24 weeks provided effective glycemic control
similar to the younger population.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
The prevalence of diabetes is increasing in Taiwan.1,2 Diabetes is
highly prevalent in elderly people. The rate of prevalence is ~20% of
the population aged 65 years in Taiwan,1,2 which presents a great
burden to individuals, society, and health care services.
The management of elderly patients with type 2 diabetes mel-
litus (T2DM) has become more complicated because of age-relatedre that they have no conﬂicts
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tric Emergency & Critical Care Mephysiological changes and the impact of comorbidities, complica-
tions and hypoglycemia.3e5 Recently, long-acting insulin analogues
were designed to mimic physiological basal insulin secretion.6,7
Insulin glargine has been well proven, in addition to oral agents,
to control fasting blood glucose with a low risk of hypo-
glycemia.8e10 In clinical practice, basal insulin is a common choice
for insulin initiation in patients with T2DM uncontrolled with oral
antidiabetic drugs (OAD).11e13 However, there was limited data to
compare effectiveness and tolerability of basal insulin therapy in
elderly population versus the younger population in clinical
practice.
The present study was performed to compare the effectiveness
and tolerability of basal insulin therapy with insulin glargine be-
tween older ( 65 years) and younger (< 65 years) T2DM patients
with inadequate control by OAD.dicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics of the patients.
Characteristics 65 y
n ¼ 32
<65 y
n ¼ 40
Age (y)* 72.5 ± 5.3 52.6 ± 8.1
Male 59.4 (19) 57.5 (23)
Female 40.6 (13) 42.5 (17)
Weight (kg) 64.1 ± 8.8 67.5 ± 16.3
BMI (kg/m2) 25.2 ± 3.6 25.3 ± 5.4
Diabetes duration (y)** 14.1 ± 6.8 10.5 ± 4.9
Patients with diabetic nephropathy 25.0 (8) 15.0 (6)
OAD before basal insulin
Metformin 56.3 (18) 75.0 (30)
Sulfonylureas 87.5 (28) 80.0 (32)
DPP-4 inhibitors 56.3 (18) 47.5 (19)
TZD 16.5 (5) 57.5 (23)
AGI 40.6 (13) 30.0 (12)
Glinides 9.4 (3) 15.0 (6)
OAD with basal insulin
Metformin 37.5 (12) 57.5 (23)
Sulfonylureas 75.0 (24) 52.5 (21)
DPP-4 inhibitors 28.1 (9) 17.5 (7)
TZD 0 (0) 20.0 (8)
AGI 25.0 (8) 12.5 (5)
Glinides 6.3 (2) 15.0 (6)
Number of OAD types before basal insulin, 2.66 ± 0.83 3.05 ± 0.90
Number of OAD types with basal insulin 1.72 ± 0.77# 1.75 ± 1.01***
Data are presented as % (n) or mean ± SD.
* p < 0.0001 for intergroup comparison.
** p ¼ 0.0119 for intergroup comparison.
*** p < 0.0001 for before and after basal insulin comparison.
AGI ¼ alpha glucosidase inhibitors; BMI ¼ body mass index; DPP-4
inhibitors ¼ dipeptidyl peptidase-4 inhibitors; OAD ¼ oral antidiabetic drugs;
SD ¼ standard deviation; TZD ¼ thiazolidinediones.
Figure 1. (A) Mean HbA1c and (B) mean FPG at baseline (before basal insulin initia-
tion) and after 24 weeks of treatment in the older group ( 65 years) and the younger
group (< 65 years). * p ¼ 0.0302 for intergroup comparison at baseline. FPG ¼ fasting
plasma glucose; HbA1c ¼ glycated hemoglobin.
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2.1. Study design and patients
This data analysis was performed using an insulin registry from
2010 to 2012 in Mackay Memorial Hospital, Taipei, Taiwan. Insti-
tutional Review Board approval was obtained for this registry and
written informed consent was obtained from each patient in the
registry. Patients were identiﬁed and included for this analysis if
they met the following criteria: patients should be  20 years old,
have a diagnosis of T2DM on OAD for  24 weeks with glycated
hemoglobin (HbA1c) > 7%, initiate once daily basal insulin therapy
with insulin glargine in an outpatient setting, and continue the
treatment for 24 weeks. Patients should also have HbA1c tests at
baseline (before initiation of insulin) and at 24 weeks. For com-
parison purposes, the patients were divided into an older group (
65 years) and a younger group (< 65 years). We also compared
patients with and without hypoglycemic episodes to analyze which
factors were associated with occurrence of hypoglycemia.
2.2. Evaluation
The effectiveness of the treatment was measured by the change
in HbA1c between the two groups after 24 weeks of treatment. We
also measured fasting plasma glucose (FPG), body weight, and
recorded the hypoglycemic episodes and other adverse events (AE)
during the basal insulin treatment period.
2.3. Statistical analysis
For quantitative data, the Student t test was used for before- and
after-treatment comparisons and for intergroup comparisons.
Qualitative variables were compared using Fisher's exact tests or
Chi-square tests. A p value < 0.05 was considered to be signiﬁcant.
3. Results
Thirty two patients with T2DM in the older group and 40 pa-
tients in the younger groupwere included for analysis. The baseline
characteristics in both groups are shown in Table 1. The mean age
(standard deviation, SD) was 72.5 (5.3) years in the older group and
52.6 (8.1) years in the younger group (p < 0.0001 for intergroup
comparison); themean diabetes durationwas 14.1 (6.8) years in the
older group and 10.5 (4.9) years in the younger group (p ¼ 0.0119
for intergroup comparison). All patients were receiving OAD
including metformin, sulfonylureas, dipeptidyl peptidase 4 (DPP-4)
inhibitors, thiazolidinediones (TZD), alpha-glucosidase inhibitors
(AGI), and glinides before and at initiation of basal insulin therapy
(Table 1). More patients in the younger group were treated with
metformin and TZD than those in the older group before or after
initiation of basal insulin therapy. The number of OAD types was
signiﬁcantly reduced on initiation of basal insulin in both the older
group (p < 0.0001) and the younger group (p < 0.0001).
At baseline, the mean HbA1c were not different between these
two groups (Figure 1). However, the FPG at baseline was slightly
higher in the younger group than that in the older group
(p ¼ 0.0302 for intergroup comparison; Figure 1). Initiating basal
insulin treatment with insulin glargine signiﬁcantly reduced HbA1c
and FPG in both groups at 24 weeks compared with baseline values
(Figure 1). HbA1c and FPG were reduced by 1.18 ± 1.76%
(p¼ 0.0006) and 81.3 ± 79.9mg/dL (p< 0.0001), respectively, in the
older group. In the younger group, HbA1c and FPGwere reduced by
1.49 ± 2.12% (p < 0.0001) and 93.0 ± 82.5 mg/dL (p < 0.0001),
respectively. However, there was no statistically signiﬁcant differ-
ence between the two groups for the reductions in HbA1c
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intergroup comparison). At 24 weeks, an HbA1c level < 7% was
achieved by 6.25% of patients in the older group and 7.5% of patients
in the younger group (p ¼ 0.8358 for intergroup comparison). An
FPG level < 130 mg/dL was achieved by 50.0% of patients in the
older group and 37.5% of patients in the younger group (p ¼ 0.2871
for intergroup comparison).
The mean daily insulin dose was slowly increased from
0.24 ± 0.11 U/kg (15.38 ± 6.54 U) at baseline to 0.36 ± 0.12 U/kg
(23.78 ± 9.68 U) at 24 weeks in the older group and from
0.27 ± 0.13 U/kg (17.55 ± 8.38 U) to 0.38 ± 0.15 U/kg
(26.55 ± 12.11 U) in the younger group. The daily insulin doses used
in both groups were similar and without signiﬁcant difference.
After initiation of insulin glargine, the mean body weight
increased signiﬁcantly from 64.1 ± 8.8 kg at baseline to
65.3 ± 8.5 kg at 24 weeks in the older group (p ¼ 0.0025) and from
67.5 ± 16.3 kg to 69.4 ± 16.3 kg in the younger group (p < 0.0001).
The mean change in weight showed no difference between these
two groups (þ1.3 ± 2.2 kg in the older group and þ1.9 ± 2.7 in the
younger group; p ¼ 0.2874 for intergroup comparison).
Three patients (9.4%) in the older group and six patients (15.0%)
in the younger group experienced at least one hypoglycemic event
(p ¼ 0.4733 for intergroup comparison). Only one severe hypogly-
cemic event was reported in the younger group. No other AE related
to insulin therapy was found.
We analyzed the factors between the patients with and without
hypoglycemic episodes in Table 2. It shows that the body mass
index (BMI) at baseline was signiﬁcantly lower in the patients with
hypoglycemic episodes than in the patients without hypoglycemic
episodes. In addition, the body weight gain after 24 weeks of in-
sulin glargine in the patients with hypoglycemic episodes was
signiﬁcantly higher than that in the patients without hypoglycemic
episodes.
4. Discussion
In elderly patients with T2DM, addition of once-daily basal in-
sulin with insulin glargine is a simple regimen to initiate insulin
therapy. The results presented here demonstrate that initiation of
insulin glargine in patients aged 65years inadequately controlledTable 2
Comparison of patients with and without hypoglycemic episodes.
Variable Patients with
hypoglycemia
n ¼ 9
Patients without
hypoglycemia
n ¼ 63
p
Age (y) 56.4 ± 14.0 62.1 ± 11.8 0.276
Sex 0.070
Male 88.9 (8) 54.0 (34)
Female 11.1 (1) 46.0 (29)
Weight (kg) 60.2 ± 8.1 66.8 ± 14.0 0.059
BMI (kg/m2) 21.9 ± 2.9 25.7 ± 4.7 0.004
Diabetes duration (y) 12.2 ± 7.6 12.1 ± 5.9 0.954
Diabetic nephropathy at baseline 11.1 (1) 20.6 (13) 0.675
Baseline HbA1c 10.66 ± 1.93 10.02 ± 1.86 0.373
Baseline FPG (mg/dL) 225.1 ± 73.1 238.6 ± 68.0 0.611
OAD types before basal insulin 2.89 ± 0.78 2.87 ± 0.91 0.956
OAD types with basal insulin 2.22 ± 0.83 1.67 ± 0.90 0.091
HbA1c at Week 24 (%) 8.48 ± 2.15 8.78 ± 1.33 0.688
FPG at Week 24 (mg/dL) 144.7 ± 64.0 149.8 ± 57.8 0.824
Daily dose at Week 24 (U) 19.7 ± 8.7 26.1 ± 11.2 0.069
Daily dose at Week 24 (U/kg) 0.30 ± 0.11 0.38 ± 0.14 0.056
Change in HbA1c (%) 2.18 ± 1.90 1.23 ± 1.95 0.194
Change in FPG (mg/dL) 80.4 ± 55.5 88.8 ± 84.3 0.699
Change in body weight (kg) þ4.7 ± 3.4 þ1.2 ± 2.0 0.014
Data are presented as % (n) or mean ± SD.
BMI ¼ body mass index; FPG ¼ fasting plasma glucose; HbA1c ¼ glycated hemo-
globin; SD ¼ standard deviation.on OAD could provide similar effectiveness on glycemic control to
younger patients. The HbA1c and the FPG were signiﬁcantly
reduced after a 24-week treatment of insulin glargine in both
groups. The rates of hypoglycemia were low and did not differ
markedly in the older patients and the younger patients. Only one
severe hypoglycemic event occurred in the younger group.
The results from this study are consistent with the results re-
ported from a clinical trial in the elderly subgroup14 and the overall
patient population.9 Similar results were also found in a pooled
analysis to compare the glycemic control in patients aged  65
years with patients aged < 65 years from ﬁve randomized
controlled trials.15 The pool analysis showed that there was no
statistical difference between the age groups in HbA1c, FPG, or
insulin dose.15 In addition, there was also no greater risk of
symptomatic or severe hypoglycemia found in adults aged  65
years than in younger adults.15 The results of the LIGHT study in
clinical practice in France indicated that the younger patient group
achieved a slightly greater reduction in HbA1c, and a larger pro-
portion of younger patients achieved HbA1c < 7.0%, compared with
the elderly patients after 3 months of long-acting insulin therapy.16
However, FPG, insulin dose and overall hypoglycemia were com-
parable in the elderly and younger patients.16
In the clinical trials after 24 weeks of initiating basal insulin
therapy, the proportion of patients who achieved HbA1c < 7% was
high (~50%).8,9,14 In the studies in real world practice, the rates of
type 2 diabetic patients on basal insulin who reached HbA1c < 7%
were 17.1% in Japan13 and 33.7% in other Asian countries.12 How-
ever, the rate of overall hypoglycemia was high (~50%) in the ran-
domized controlled trials of insulin glargine or other basal insulins
in patients with T2DM with inadequate glycemic control to
OAD.9,17e20 It may be due to the differences between trial settings
and real world practice, for example, characteristics of patients,
treatment targets, frequency of self-monitoring of blood glucose,
and methods of insulin dose titration.
This analysis found that the number of OAD types was signiﬁ-
cantly reduced in both groups on initiation of basal insulin therapy
with insulin glargine. The LIGHT study in France showed a similar
pattern of OAD use before and after insulin initiation.16 However, an
observational study in Asia for T2DM demonstrated that the
number of OADs was almost unchanged at the start of basal insulin
therapy.12 This might be due to different physicians who had in-
dividual practice styles and variations in clinical judgment.
Although glycemic control may provide beneﬁts for many
elderly patients with T2DM, the risk of hypoglycemia is of partic-
ular concern for management of diabetes.21 Elderly people with
diabetes are at higher risk than younger adults for hypoglycemic
events. Diminished intensity of hypoglycemic symptoms, fewer
individual symptoms, and attenuated counter-regulatory hormonal
responses have been observed in elderly diabetic patients.22
Moreover, a study demonstrated that the frequency and grouping
of hypoglycemic symptoms in elderly insulin-treated diabetic pa-
tients may be different from those of younger adults.23 These
concerns might be reﬂected in the use of basal insulin therapy in
the elderly. This study also identiﬁed lower BMI and higher weight
gain were signiﬁcantly associated with the occurrence of hypo-
glycemia. A previous study demonstrated that although multiple
factors contributed to insulin sensitivity, BMI was the strongest
predictor.24 This indicated that caution should be practiced with
regard to hypoglycemia on initiation of insulin therapy in patients
with a lower BMI. In addition, hypoglycemia can result in weight
gain because of excessive food intake to avoid future
hypoglycemia.25
Glycemic target goals for T2DM in the elderly population might
be different from those in the younger population. The new
American Diabetes Association-European Association for the Study
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patient-centered approach is necessary, balancing the beneﬁts of
glycemic control with its potential risks, taking into account age,
life expectancy, health status, and risk of hypoglycemia for targets
of glucose control.26 In order to minimize risk of hypoglycemia in
elderly patients, HbA1c treatment goals may be less restrictive for
elderly people who are frail.27
Insulin therapy is a useful tool in the elderly population because
of the high frequency of comorbidities that may preclude the use of
certain OADs.27 Physicians should tailor antidiabetic therapy for
elderly patients according to medical status, comorbidities, and
ability to use insulin devices and understand the risks associated
with insulin therapy, e.g., hypoglycemia.27 Long-acting insulin an-
alogues possess different physiological proﬁles compared to human
Neutral Protamine Hagedorn (NPH) insulin.6,7 Moreover, long-
acting insulin analogues are more convenient to administer and
are associated with a lower incidence of hypoglycemia.5,8e10,27 The
ﬁndings of this study may give primary care physicians more
conﬁdence in initiation of basal insulin treatment in elderly
patients.
There are several potential limitations to the study analysis.
First, this analysis was not intended to prove a causal relationship in
efﬁcacy in both age groups between insulin glargine and
improvement of glycemic control but was reﬂective of real-world
clinical practice. Second, the insulin dose and the glycemic con-
trol might not be optimized within a 24-week treatment period.
Third, the generalizability of ﬁndings could be limited because of
the sample selection and the small sample size. Fourth, lack of
signiﬁcant differences may be due to the limitations of small
sample size. Fifth, the diabetic nephropathy which was reported by
physiciansmight be underestimated ormisclassiﬁed due to the lack
of precise deﬁnition and the estimated glomerular ﬁltration rate
(eGFR) levels not being collected.
In conclusion, our results suggest that initiating basal insulin
therapy with insulin glargine in elderly patients with OAD may
provide effective glycemic control on HbA1c and FPG similar to
those in younger patients. The rates of hypoglycemia and tolera-
bility proﬁles are comparable in elderly and younger patients. This
may be used as a reference for physicians who are considering
initiating basal insulin therapy in elderly patients with T2DM in
clinical practice.
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